Literature DB >> 23571428

Ion mobility spectrometry-mass spectrometry analysis for the site of aromatic hydroxylation.

Atsushi Shimizu1, Masato Chiba.   

Abstract

Hydroxylated metabolites often retain the pharmacological activity of parent compound, and the position of hydroxylation determines the formation of chemically reactive intermediates, such as quinones and analogs, from para- and/or ortho-hydroxylation of phenols or arylamines. Therefore, the identification of exact position of hydroxylation is often required at the early development stage of new drug candidates. In many cases, liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides identical MS/MS spectra among isomeric hydroxylated metabolites, and therefore, it alone cannot unequivocally identify the exact position(s) of hydroxylation. Ion mobility spectrometry (IMS), integrated with LC-MS/MS, recently showed the capability of separating isomeric species based on differences in their drift times from IMS, which are linearly proportional to the collision cross-section (CCS) reflecting physical size and shape. In the present study, a chemical derivatization of isomeric hydroxylated metabolites with 2-fluoro-N-methyl pyridinium p-toluenesulfonate was found to confer distinct theoretical CCS value on each isomer by forming corresponding N-methyl pyridine (NMP) derivative. The regression lines established by the comparison between theoretical CCS values and observed drift times from IMS for each set of parent compound (labetalol, ezetimibe, atorvastatin, and warfarin) and its MS/MS product ions accurately and selectively projected the actual drift times of NMP derivatives of corresponding aromatic or isomeric hydroxylated metabolites. The established method was used for the accurate assignment of predominant formation of 2-hydroxylated metabolite from imipramine in NADPH- fortified human liver microsomes. The present application expands the versatility of LC-IMS-MS technique to the structure identification of isomeric hydroxylated metabolites at the early stage for drug development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571428     DOI: 10.1124/dmd.113.051953

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Characterization of the Impact of Drug Metabolism on the Gas-Phase Structures of Drugs Using Ion Mobility-Mass Spectrometry.

Authors:  Dylan H Ross; Ryan P Seguin; Libin Xu
Journal:  Anal Chem       Date:  2019-10-29       Impact factor: 6.986

Review 2.  Predicting drug metabolism: experiment and/or computation?

Authors:  Johannes Kirchmair; Andreas H Göller; Dieter Lang; Jens Kunze; Bernard Testa; Ian D Wilson; Robert C Glen; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2015-04-24       Impact factor: 84.694

Review 3.  Ion Mobility Collision Cross Section Compendium.

Authors:  Jody C May; Caleb B Morris; John A McLean
Journal:  Anal Chem       Date:  2016-12-28       Impact factor: 6.986

4.  Large-Scale Structural Characterization of Drug and Drug-Like Compounds by High-Throughput Ion Mobility-Mass Spectrometry.

Authors:  Kelly M Hines; Dylan H Ross; Kimberly L Davidson; Matthew F Bush; Libin Xu
Journal:  Anal Chem       Date:  2017-08-22       Impact factor: 6.986

5.  Using LC Retention Times in Organic Structure Determination: Drug Metabolite Identification.

Authors:  William L Fitch; Cyrus Khojasteh; Ignacio Aliagas; Kevin Johnson
Journal:  Drug Metab Lett       Date:  2018

6.  Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph-Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice.

Authors:  Francesca Ferlenghi; Carmine Giorgio; Matteo Incerti; Lorenzo Guidetti; Paola Chiodelli; Marco Rusnati; Massimiliano Tognolini; Federica Vacondio; Marco Mor; Alessio Lodola
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.